What is the state of the outsourcing industry?
What are the future prospects?
The PCMG Annual Conference in Sitges during 7-9 June will consider the outsourcing landscape in this state of the industry address, provocatively entitled “There will be Dragons!” Find out more and register at https://www.pcmg.org.uk/events/conference2019
This ‘state of the industry’ address will provide a broad and detailed analysis of the industry; the evolution, the market dynamics, the prospects for investment, the emergence of new players, the external pressures and their impacts on outsourcing dynamics and the future outsourcing models that will support world class drug development, including all of the seven C’s to be covered in the conference.
A huge topic in itself, we are delighted to confirm the challenge of presenting this session has been accepted by John Hubbard, Ph.D., FCP, a member of Genstar Capital’s Strategic Advisory Board and an industry luminary with a long list of achievements in both Pharma and CRO-land.
John has enjoyed more than 33 years of leadership experience in the biopharmaceutical and pharma services industries, including roles as President and Chief Executive Officer of Bioclinica; Senior Vice President and Worldwide Head of Development Operations at Pfizer where he was also a founding member of the Board of Directors of TransCelerate Biopharma Inc. and Group President of ICON plc’s Global Clinical Research Services Division. In addition John held executive positions at Parexel International Corporation and Sanofi Pharmaceuticals. He is currently a Board Member of CRF Bracket (a portfolio company of Genstar) and Agile Therapeutics (NASDAQ: AGRX) where he is Chairman of the Science and Technology Committee and also serves on the Audit Committee. He is an Executive Committee Member on the Clinical Trials Transformation Initiative, Board Member of Life Sciences PA and former Chairman of the Board of the Association of Clinical Research Organizations (ACRO)